在败血症引起的凝血病中对阿尔加特罗班的评估:基于MIMIC-IV数据库的回顾性研究
Jiaqi Tang1,2, Hongguang Ding3, Zhiwei Su2
1Department of Critical Care Medicine, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
概括
在ICU的败血症诱导凝血病 (SIC) 患者中使用Argatroban与增加的死亡率有关. 这项研究表明Argatroban不推用于SIC抗凝剂治疗,强调需要替代治疗方法.
科学领域:
- 关键护理医学 关键护理医学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 败血症引起的凝血病 (SIC) 是重症监护室 (ICU) 患者经常出现的致命并发症.
- 目前缺乏关于Argatroban在SIC抗凝剂治疗中的有效性和安全性的证据.
研究的目的:
- 调查阿尔加特罗班使用与患有败血症诱导凝血病患者的预后之间的关联.
- 评估Argatroban作为SIC中的抗凝剂的安全性和有效性.
主要方法:
- 一项使用MIMIC-IV数据库的回顾性研究.
- 倾向分数匹配 (PSM) 用于比较Argatroban用户与非用户.
- 考克斯回归和卡普兰-梅尔分析评估30天死亡风险.
主要成果:
- 在PSM之后,接受阿加特罗班的108名患者与108名对照进行了匹配.
- 阿格特罗班的使用与SIC患者30天死亡风险显著增加有关 (HR=1.800,P=.043).
结论:
- 在患有败血症诱导的凝血病的患者中,不建议使用阿尔加特罗班作为抗凝血剂治疗.
- 研究结果表明,在这种患者群体中,与Argatroban相关的潜在危害.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Venous Thrombosis III: Interprofessional Care
257
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
257
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
274
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
274
Acute Kidney Injury IV: Diagnostic Studies and Prevention
242
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
242
Coagulation
9.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.5K


